← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 160개
ADCAFDAFDABiologicstaleAbbViePhase 3

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Advanced Solid Tumors Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase3#FDA승인#항체약물접합체+3
효능 ORR 33.3%임상시험 12상태 RECRUITING
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 648상태 RECRUITING
AntibodyAHotEli Lilly-linkersPhase 2

EGFR inhibitor (Cetuximab, Cetuximab (EGFR inhibitor))

Advanced Solid Tumor; NSCLC · EGFR

#EGFR#Antibody#Phase2#인기#항체+5
효능 ORR 70.6%임상시험 166상태 ACTIVE
ADCBHotBiologicDaiichi SankyoPhase 1

DP (DS-8201a, DS-8201a (DP))

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#인기#항체약물접합체+2
효능 ORR 69.7%임상시험 107상태 ACTIVE
AntibodyBHotBeiGeneVedotin, Tislelizumab, and …Phase 1

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#인기#항체+5
효능 ORR 68.3%임상시험 105상태 RECRUITING
AntibodyCBeiGeneVedotin, Tislelizumab, and …Phase 2

Tislelizumab (Tislelizumab)

Locally Recurrent Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 37.1%임상시험 96상태 RECRUITING
ADCCBiologicShanghai Hansoh Biomedical Co.,…GQ1001Phase 1

Phase Ia: Dose escalation (HS-20093, HS-20093 (Phase Ia: Dose escalation))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#인기#항체약물접합체+4
임상시험 79상태 ACTIVE
ADCBBiologicAmgensPhase 3

Sunitinib (Sunitinib)

Advanced Solid Tumors · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 78%임상시험 76상태 RECRUITING
ADCBiologicHansoh BioMedical R&D Companyvedotin with pembrolizumabPhase 3

Cisplatin / carboplatin (Cisplatin / carboplatin)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 84%임상시험 67상태 RECRUITING
AntibodyShanghai Shengdi Pharmaceutical…vedotin (RC48) in combinati…Phase 2

Adebrelimab (Adebrelimab)

Pancreatic Cancer · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#인기#항체+5
임상시험 66상태 RECRUITING
ADCBiologicDaiichi SankyoDM1) and trastuzumab deruxt…Phase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

Breast Cancer; HER2-positive Breast Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 65.8%임상시험 66상태 RECRUITING
AntibodyAstraZenecavedotin combined with pembr…Phase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#인기#항체+5
효능 ORR 36.3%임상시험 65상태 ACTIVE
ADCBiologicDaiichi SankyoreleasePhase 1

DP1 (DS-8201a, DS-8201a (DP1))

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#인기#항체약물접합체+4
효능 ORR 79.7%임상시험 64상태 ACTIVE
CGTBiologicTurnstone Biologics, Corp.Phase 1

RT-01 (Oncolytic Virus Injection, Oncolytic Virus Injection(RT-01))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#CGT#Phase1#인기#세포유전치료+4
효능 ORR 28%임상시험 60상태 ACTIVE
AntibodyRocheDM1) and trastuzumab deruxt…Preclinical

trastuzumab (Herceptin, Trastuzumab + Pertuzumab)

Solid Tumor; Advanced Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Preclinical#인기#항체+5
효능 ORR 79.5%임상시험 60상태 RECRUITING
AntibodyRochePreclinical

Bevacizumab + Erlotinib (Bevacizumab + Erlotinib)

Solid Tumor; Advanced Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Preclinical#인기#항체+4
효능 ORR 72%임상시험 52상태 RECRUITING
ADCBiologicStrata OncologyPhase 2

encorafenib + binimetinib (encorafenib + binimetinib)

Cancer; Advanced Solid Tumor · Cancer

#Cancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 66.7%임상시험 48상태 DISCONTINUED
ADCBiologicSichuan Baili Pharmaceutical Co…viaPhase 2

BL-B01D1 (BL-B01D1)

Rare Malignant Neoplasm; Advanced Solid Tumors · Rare Malignant Neoplasm

#RareMalignantNeoplasm#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 44상태 RECRUITING
AntibodyAnaveon AGVedotin ± Pe…Phase 2

KEYTRUDA® (ANV600 + pembrolizumab, ANV600 + pembrolizumab (KEYTRUDA®))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+4
효능 ORR 71.4%임상시험 31상태 RECRUITING
ADCBiologicBeOne MedicinesPhase 1

Anticancer Agents (Anticancer Agents)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 0%임상시험 31상태 RECRUITING

1 / 8 페이지

← 이전다음 →